Peer-reviewed veterinary case report
Safety of doxorubicin and cyclophosphamide chemo in dogs with tumors
By Rasmussen, R M et al.·Published in Veterinary and comparative oncology·2017·Department of Medical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
- Species:
- dog
Plain-English summary
A group of dogs with tumors received a combination of two chemotherapy drugs, doxorubicin and cyclophosphamide, to see how safe it was and how it affected their immune system. The treatment was found to be safe, but both drugs caused a drop in certain immune cells in the dogs. This means that while the combination therapy didn't specifically target the immune cells, it still had an overall impact on their immune system. Further studies are needed to understand the best ways to use these treatments together for dogs with cancer.
People also search for: dog cancer treatment doxorubicin cyclophosphamide · chemotherapy side effects in dogs · immune system effects of dog cancer drugs
Abstract
Maximally tolerated dose (MTD) and metronomic dose chemotherapeutic approaches alter the immune system and the angiogenic process in different yet potentially complementary ways. A combination of MTD doxorubicin (MTD-DOX) and metronomic cyclophosphamide (mCTX) protocol was evaluated for safety and effect on circulating regulatory T (Treg) cells. We found that mCTX can be safely administered with MTD-DOX in tumour-bearing dogs. Both combination DOX/mCTX and single-agent DOX resulted in significant depletions of circulating lymphocytes throughout the chemotherapy cycle without apparent selectivity for Tregs. The indiscriminant lymphocyte depletions were similar between dogs randomized to receive DOX and dogs randomized to receive DOX/mCTX, suggesting this effect is because of DOX alone. These findings may have implications as to the therapeutic benefit (or lack thereof) of concurrent combination MTD and metronomic protocols. Future investigations are required to determine the effects and indeed the efficacy of concurrent versus sequential applications of MTD and metronomic chemotherapy protocols.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26522053/